Background and Objectives We evaluated the phenotypic and functional distinction between B cells with receptors for human blood group A and B determinants in a-galactosyltransferase-deficient (GalT À/À ) mice.
Introduction
The immunodominant structures of blood group A and B antigens are defined as N-acetyl-D-galactosamine (GalNAc) a1-3(Fuca1-2)Gal and Gala1-3(Fuca1-2)Gal, respectively [1, 2] . Functional A and B alleles encode the A and B transferases, which transfer GalNAc and galactose to the same acceptor H substrates (Fuca1-2Gal), and synthesize the A and B antigenic determinants, respectively. Although the use of ABO-incompatible donor organs is an alternative solution to combat the shortage of donor organs for transplantation, the production of antibodies (Abs) against the blood group A or B carbohydrate epitopes in recipient serum is a major impediment to the success of this approach. Plasmapheresis or plasma exchange, splenectomy, and anti-B-cell immunosuppressant treatment, including rituximab, in the recipient are widely adopted strategies to remove anti-A, anti-B, or both Abs and prevent the Ab-mediated rejection (AMR) of ABO-incompatible organ grafts [3, 4] . Owing to these therapeutic approaches, graft survival in ABO-incompatible organ transplantation is not currently inferior to that in ABO-compatible transplantation [5, 6] . However, the use of non-specific immunosuppressive treatments is likely to increase the incidence of infectious complications such as cytomegalovirus infection [7, 8] . Therefore, optimizing the immunosuppressive regimen might further improve the outcome of ABO-incompatible organ transplantation. For this purpose, identification of the B cell clones responding to A/B carbohydrates and determination of their sensitivity to immunosuppressants is required; however, the limited availability of appropriate animal models has thus far been an obstacle in conducting comprehensive evaluations of B cells.
Previous experiments by our group and other researchers showed significant levels of naturally occurring antihuman blood group A-determinant Abs but undetectable levels of anti-human blood group B-determinant Abs in the sera from several strains of mice [9, 10] . The absence of anti-B Abs might be explained by the presence of Blike structures in mouse cells, that is Gala1-3Galb1-4GlcNAc (Gala1-3Gal) carbohydrate residues, which are completely lacking in human cells because of a-galactosyltransferase deficiency. The inborn expression of Gala1-3Gal in various cells in mice likely maintains B-cell tolerance towards B determinants. Supporting this hypothesis, in this present study, we found that a-galactosyltransferase-deficient (GalT À/À ) mice, which are completely deficient in Gal epitopes, showed elevated anti-A and anti-B Abs in the sera after immunization with AB-RBCs, thereby resembling the response in blood group O humans. Utilizing these GalT À/À mice as an animal model, we further evaluated the phenotypic and functional distinction between B cells with receptors for human blood group B determinants and those with receptors for A determinants.
Materials and methods

Mice
Balb/c and C57BL/6J (B6) mice were purchased from CLEA Japan (Tokyo, Japan). The GalT À/À mice in the B6 background, which completely lack Gal expression, were kindly provided by Dr. M. Sykes, Massachusetts General Hospital, MA, USA [11] . All the mice were used at 8-12 weeks of age. All experiments were approved by the Institutional Review Board of Hiroshima University and were conducted in accord with the guidelines of the National Institutes of Health (NIH publication No. 86-23, revised 1996).
In vivo In vivo immunization with human RBCs
Fresh human peripheral blood samples were collected from volunteers with blood group A, B or AB. Informed consent was obtained from all volunteers in accordance with the Declaration of Helsinki. For in vivo immunization, a suspension of 1 9 10 9 human A-or B-RBCs in 1 ml phosphate-buffered saline (PBS) was injected into the peritoneal cavity (PerC) of each mouse twice in 1-week intervals. When indicated, cyclosporine A (CsA; Novartis, Basel, Switzerland) was administered daily intraperitoneally at 10 mg/kg/day for 4 weeks. One and 2 weeks after commencing CsA treatment, the GalT À/À mice were immunized with human blood group AB-RBCs.
Cell preparation and flow cytometry (FCM) analyses
After harvesting the spleens (Spls) from mice and erythrocyte lysis with an ammonium chloride/potassium solution, the splenocytes were suspended in PBS. PerC cells were isolated by peritoneal lavage using cold PBS. B cells with receptors for human blood group A and B trisaccharides were detected using fluorescein isothiocyanate (FITC)-conjugated GalNAca1-3Fuca1-2Gal-bovine serum albumin (BSA) (A-BSA: Dextra, Reading, UK), a-l-Fuc- The biotinylated mAb was visualized using allophycocyanin-streptavidin. Isotype-matched irrelevant mAbs were used as a control. All mAbs were purchased from BD PharMingen (San Diego, CA, USA). Dead cells were excluded from the analysis based on light scattering and staining with propidium iodide.
Myeloid differentiation factor 88 (MyD88) expression was detected by intracellular staining using the affinitypurified polyclonal goat anti-mouse/rat MyD88 Ab (R&D Systems, Minneapolis, MN, USA) followed by allophycocyanin-conjugated anti-goat IgG secondary Ab (clone SC-2024; R&D Systems, Minneapolis, MN, USA). Cells were fixed and permeabilized in Cytofix/Cytoperm buffers (BD Biosciences) following the manufacturer's protocol, and permeabilized with saponin.
Four-colour FCM was performed on a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA, USA). Data were analysed using FlowJo 7.6.5 software (TreeStar, San Carlos, CA, USA).
Cell sorting
Spl cells were sorted under sterile conditions using a SORPAria cell sorter (Becton Dickinson, Mountain View, CA). Sorted cells were reanalysed for purity on a FACSCalibur flow cytometer, and were immediately resuspended in culture medium and applied to ELISPOT plates precoated with B-BSA or anti-mouse IgM to determine the frequency of IgM-producing cells.
Enzyme-linked immunosorbent assay (ELISA)
The levels of anti-A or -B-specific Abs in sera were determined by ELISA as described previously [10, 12] . In brief, ELISA plates were coated with 5 lg/ml synthetic A-or B-BSA (Dextra) or control BSA (Roche). Diluted serum samples were incubated in the plates, and bound Abs were detected using horseradish peroxidase-conjugated goat anti-mouse IgG/IgM-specific Abs (IgM: KPL, Guilford, UK, IgG: Jackson ImmunoReserch). Colour development was achieved using 0Á1 mg/ml O-phenylenediamine (Sigma, St. Louis, MO, USA). The reaction was stopped by the addition of 3 M H 2 SO 4 , and absorbance was measured at 492 nm.
Enzyme-linked immunospot (ELISPOT) assay
An ELISPOT assay to detect Ab-producing cells was performed as described previously [13] . In brief, nitrocellulose membranes of a 96-well filtration plate (Millipore, Bedford, MA, USA) were coated with 5 lg/ml B-BSA or control BSA for detecting anti-B IgM/IgG-producing cells. Serial dilutions of the cell suspension in Iscove's modified Dulbecco medium (IMDM; Sigma) supplemented with 0Á4% BSA, 5 lg/ml insulin (Sigma), 5 lg/ml transferrin (Sigma), 5 ng/ml sodium selenite (Sigma), 50 lM 2-mercaptoethanol (Katayama, Osaka, Japan), and 1 lg/ml gentamicin were added to wells. After 24 h of culture, bound Abs were detected using horseradish peroxidase-conjugated goat anti-mouse IgM/IgG Abs (IgM: KPL, IgG: Jackson ImmunoReserch), followed by colour development with 3-amino-9-ethyl carbazole (Sigma).
In vitro In vitro B-cell proliferation assay
The resting B cells were isolated from the splenocytes of untreated Balb/c mice by negative selection using a B-cell isolation kit and an automagnetic-associated cell sorter (MACS) (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions. The B cells were labelled with 5 lM of 5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR, USA), as described previously [14] . The CFSE-labelled cells were cultured in Roswell Park Memorial Institute (RPMI; Nacalai Tesque, Kyoto, Japan) culture medium, 5 lM 2-mercaptoethanol, 1% HEPES buffer (GIBCO, Grand Island, NY, USA), and 100 IU/ml penicillin/100 lg/ml streptomycin (GIBCO). To differentiate resting B cells to B-1 cells, the B cells were treated with 20 lg/ml of goat anti-mouse IgM F (ab') 2 (Jackson Immuno Research Laboratories, West Grove, PA); an analogue of T-cell-independent type 2 (TI-2) antigens (Ags). When indicated, the B cells were treated with a combination of 20 lg/ml of anti-IgM F(ab') 2 and 10 lg/ml Escherichia coli lipopolysaccharide (LPS; serotype 0111:B4; Sigma), an agonist of Toll-like receptor (TLR)4. To differentiate resting B cells to B-2 cells, the Bcells were activated with irradiated feeder cells of 3T3 fibroblasts transfected with CD40L and B cell activation factor (BAFF) provided by Dr. Daisuke Kitamura, Division of Molecular Biology, Research Institute for Biological Sciences, Tokyo University of Science [15] and 0Á02 lg/ml recombinant mouse IL-4 (R&D Systems, Minneapolis, MN, USA). The cultures were incubated for 3 days. The cultivated cells were stained with PE-conjugated CD19 (1D3) or biotinylated CD5 (53-7Á3) mAbs. The biotinylated mAbs were visualized using allophycocyanin-streptavidin, followed by 4-colour FCM analyses. Dead cells, identified by light scatter and propidium iodide staining, were excluded from the analyses. The precursor frequency (PF) and mitotic index (MI) were quantitatively estimated using a previously described method [16] .
Statistical analysis
The results were statistically analysed using the unpaired Student's t-test of means or analysis of variance (ANOVA). A P-value of <0Á05 was considered statistically significant. In both the WT GalT +/+ and GalT À/À mice, the frequency of cells with sIgM that bound to B-BSA (B-BSA-binding B cells) in the PerC was higher than that in the Spl (Fig. 1a  and b phenotype, which is consistent with the properties of the B-1b-like subpopulation. Thus, B cells responding to blood group B epitopes were phenotypically distinct from B-cells responding to blood group A epitopes. In response to immunization with A-RBCs (via intraperitoneal injection of 1 9 10 9 RBCs), the serum levels of anti-A Abs were remarkably elevated in both WT and GalT À/À mice (Fig. 2a) . In contrast, the elevation of serum levels of anti-B Abs in WT mice never reached the same level as those in GalT À/À mice in response to immunization with B-RBCs. Consistently, an ELISPOT assay conducted 14 days after the immunization showed that the frequency of anti-B Ab-producing cells (both IgM and IgG) in the Spl was significantly higher in GalT À/À mice than that in WT mice (Fig. 2b) . The combined FCM sorting and ELISPOT assay revealed that anti-B Ab (IgM)-producing cells were greatly enriched in the sorted B-BSA-binding IgM + population and were undetectable in the sorted B-BSA-nonbinding IgM + population (Fig. 3) , demonstrat- 
Results
B cells responding to blood group B-antigens express MyD88
Several gram-negative bacteria express histo-blood group antigens in their LPS O-chain [17, 18] . Previous chemical and serological investigations have demonstrated that the strong blood group activity of E. coli O86 is derived from 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 LPS containing the blood group B trisaccharide partial structure [19, 20] . This fact prompted us to investigate whether blood group B carbohydrate determinants activate TLR4, which recognizes LPS from gram-negative bacteria, resulting in activation of the MyD88-dependent signalling pathway. For this purpose, GalT (Fig. 4) . Hence, B cells responding to blood group B-antigens were likely activated via TLR4-MyD88 signalling, distinguishing them from B cells responding to blood group A-antigens.
LPS/TLR4 signalling impaired the inhibitory effects of CsA on anti-IgM F(ab') 2 -induced B-cell proliferation
We previously demonstrated that mouse's resting splenic B cells treated with anti-IgM F(ab') 2 , an analogue of TI-2 Ags, differentiated into CD5 + B cells in vitro, whereas those treated with CD40L and IL-4, which provide thymus-dependent inductive signals, differentiated into CD5 À B-cells [21] . We also observed that a clinically relevant concentration of CsA (100 ng/ml) completely blocked CD5 + B-cell proliferation but did not inhibit CD5 À B-cell proliferation. Prior to treatments with antiIgM F(ab') 2 or BAFF/CD40L-expressing feeder cells and IL-4, resting B cells were labelled with CFSE, thereby enabling phenotypic analysis of the proliferating cells by multicolour FCM analysis. As previously demonstrated, (Fig. 5a ). The addition of CsA also inhibited the B cell proliferation induced by both anti-IgM F(ab') 2 and LPS, but the inhibitory effect was inferior to that observed with respect to B cell proliferation induced by anti-IgM F(ab') 2 alone (Fig. 5b ).
CsA inhibited anti-A Ab production, but not anti-B Ab production
To investigate the resistance to CsA's inhibitory effects on Ab production in response to blood group B-antigens, which likely activates B-1b cells via TLR4-MyD88 signaling, GalT À/À mice were daily administered intraperitoneally with CsA at 10 mg/kg/day for 4 weeks. One and 2 weeks after commencing CsA treatment, GalT À/À mice were immunized with human blood group AB-RBCs. The CsA treatment completely prevented the elevation of anti-A Ab serum levels, even after immunization with ABRBCs; however, it did not have any effect on anti-B Ab levels (Fig. 6 ). This result indicates that the sensitivity of CsA to B cells responding to B-Ags markedly differs from that of B cells responding to A-Ags.
Discussion
Mature B cells are heterogeneous and belong to four subsets in mice: follicular (FO), marginal zone (MZ), CD5 + B1a and CD5 À B-1b. FO B cells recirculate in the blood among the lymphoid follicles and mount Ab responses against T-cell-dependent protein Ags [22] . MZ B cells, which are localized proximal to the marginal sinus of the Spl, as well as B-1a and B-1b cells, which are most abundant in the peritoneal and pleural cavities, generate T-cell-independent responses [23] . Although CD5 expression is the phenotypic criterion used to distinguish B-1a from B-1b subsets, several other biological distinctions exist between these cell populations. Defects in BCR signalling more profoundly affect B-1a-cell development [24] . Furthermore, CD19 expression has been shown to be essential for the development of B-1a-but not B-1b-cells [25] . Nevertheless, both the B-1a and B-1b cell subsets seem to require unique activation signals and to react with distinct response patterns. A previous study also demonstrated a different pattern of V H family usage in B- 1b cells compared with B-1a cells in mice, suggesting divergence in the repertoires and functions of the B-1a and B-1b subsets [26, 27] . This study revealed that B cells with receptors for the blood group B epitope phenotypically belong to the B-1b-cell subset, which is distinct from B-1a cells with receptors for the blood group A epitope, in GalT À/À mice with the ability to respond to both blood group A and B antigens.
Previous investigations have demonstrated that the strong blood group activity of E. coli O86 is derived from LPS containing the blood group B trisaccharide partial structure [19, 20] . It is likely that blood group B carbohydrate determinants activate TLR4, which recognizes LPSs. In this study, we found strong expression of MyD88 in B-BSA-binding B cells in the Spl cells of GalT À/À mice immunized with B-RBCs, but MyD88 was barely detectable in A-BSA-binding B cells in the Spl cells of GalT À/À mice immunized with A-RBCs (Fig. 4) . These findings suggest that B cells responding to blood group B-antigens are activated via TLR4-MyD88 signalling, distinguishing them from B cells responding to blood group A-antigens. Both B-1a and B-1b cells are known to express TLRs and respond to ligation of TLRs. The surface expression of TLR2 and TLR4 and the intracellular expression of TLR7 and TLR9 are high in mouse B-1 cells [28] . Although certain TLR ligands such as CpG1668, LPS, R848, and Pam3CSK4 can selectively promote B-1-cell differentiation [29] , the precise roles of these TLR-signalling molecules in B-cell activation remain to be elucidated. Upon the ligation of TLR4 by LPS together with BCR crosslinking induced by anti-IgM F(ab') 2 , resting B cells were here found to phenotypically differentiated into CD5 À B-1b cells, whereas resting B cells differentiated into CD5 + B-1a cells by anti-IgM F(ab') 2 -induced BCR crosslinking without ligation of TLR4 by LPS (Fig. 5) . All of these findings seem to be consistent with the hypothesis that B cells with BCR for blood group B-antigens are activated via TLR4-MyD88 signalling together with BCR-crosslinking, distinguishing them from B cells with BCR for A-antigens, which are activated only via BCR-crosslinking. The ontogenic and functional properties of different B-1-cell subsets are of great interest in achieving a comprehensive understanding of B-cell biology. B-1a cells are drastically reduced or absent in strains with impaired classical nuclear factor-kappa B (NF-jB) signalling, whereas B-1b cells are less affected [30] . This difference in the dependence on NF-jB signalling between B-1a cells and B-1b-cells could possibly explain the observed difference between B-1b cells responding to B-Ags and B-1a-cells responding to A-Ags in the sensitivity to CsA, since BCRand BAFF-induced signalling to NF-jB is known to contribute to B-cell immune responses [31] . A recent report demonstrated that calcineurin inhibitors (CNIs) inhibit the protein phosphatase activity of calcineurin, leading to suppression of both of the nuclear translocation of NFAT and NF-jB phosphorylation as well as inhibition of T-cell activation [32] . Because it is also likely that CNIs block NF-jB activation, even in B cells, this would explain why CsA inhibited anti-A Ab production via NF-jB-dependent B-1a-cell activation, but not anti-B Ab production via NFjB-independent B-1b cell activation.
To investigate the clinical relevance of our findings described above, we analysed the data from the Japanese Transplantation Registry for ABO-incompatible livingdonor kidney transplantation. Among the whole population, we selected patients that had been treated with a CsA-based immunosuppressive regimen without pan-Bcell inhibition by either rituximab or splenectomy, and then analysed the graft survival rates. The results showed that 15 years after transplantation, the graft survival rate of recipients with B-antigen disparate grafts was significantly worse than that of recipients with A-antigen disparate grafts (Fig. S1 ), which likely reflects the difference in the sensitivity to CsA of B cells responding to blood group A and B antigens. However, there was no difference in the graft survival rate among the recipients treated with rituximab, which can deplete both B-1a and B1b cells expressing CD20 (data not shown). Thus, the decision to omit rituximab from an immunosuppressive Furthermore, B cells responding to blood group B-antigens express MyD88, suggesting the involvement of TLR signalling in Ab production against blood group B-antigens. Consistently, CsA inhibited anti-A Ab production, but not anti-B Ab production. To confirm these results, further studies with human B cells should be conducted . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 
